Drugs / CVI-LM001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04438096 | Jul 2020 → Dec 2021 | hyperlipidemia | CVI Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVI-LM001 | “The purpose of this study is to determine if CVI-LM001 is effective and safe versus placebo in drug-naive subjects with elevated LDL cholesterol.” NCT04438096 ↗ |
| Route | Oral | “will be orally administered for 12 weeks” NCT04438096 ↗ |